Diagnos $ADK #DGNOF Signs Memorandum of Understanding with #Essilor International

Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with the Instruments division of Essilor International, a subsidiary of EssilorLuxottica. Essilor International is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses and diagnostic ophthalmic instruments.

 The MoU is non-binding and forms the basis of a potential distribution agreement with Essilor International for DIAGNOS’ CARA platform for the AI-enhanced analysis of wide-field retinal images, as well as of certain specified future developments of the CARA platform for a variety of applications.

 DIAGNOS has under development multiple new applications involving AI-enhanced retinal imaging to address a growing need for general purpose pathology identification. In addition to localized retinal pathology, such as macular degeneration and glaucoma, certain retinal pathologies are also known indicators of various systemic disorders, including cardiovascular and diabetic diseases. On July 20th 2021, DIAGNOS announced a clinical trial with CommonSpirit Health Research Institute in the USA for the early detection of stroke through the inspection and analysis of the retina.

 “DIAGNOS is focused on its commercialization strategy and pursuing opportunities with potential partners. We are very pleased that our AI-based technology has attracted the attention of global eyecare sector leaders such as Essilor International and we are looking forward to our discussions with respect to a mutually beneficial potential worldwide distribution agreement. At the same time, DIAGNOS continues to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure that we stay ahead of our competition worldwide,” said Mr. André Larente, President of DIAGNOS

Triumph Gold $TIG $TIGCF Completes #Artificial #Intelligence Study at the Freegold Mountain Project, #Yukon

Triumph Gold Corp. (TSX-V: TIG | OTCMKTS: TIGCF) (“Triumph Gold” or “the Company”) is pleased to announce that it has concluded an in-depth Artificial Intelligence (“AI”) study focused on the Revenue-Nucleus Area, a large zone of gold-copper-silver-molybdenum mineralization, within their district-scale Freegold Mountain Project (“the Project”) located in Yukon, Canada (Figure 1). The Company engaged Minerva Intelligence Inc. (“Minerva”) to utilize their cutting-edge DRIVER software along with K-Means Cluster Analysis to evaluate multi-element drilling data.

Results from Minerva’s cognitive AI analysis have enhanced Triumph’s technical understanding of the Nucleus and Revenue Deposits by providing confidence in existing models and identifying unrealized controls on mineralization. Key findings are being used to guide current exploration activities at the Freegold Mountain Project, notably:

  1. At the Nucleus Deposit, DRIVER revealed new vectors to gold and copper mineralization not characterized in the current mineral resource delivering superior exploration models and a clear path forward for resource expansion,
  2. At the Revenue Deposit, DRIVER has identified under-evaluated areas at northeast and southern contacts of the diatreme providing credible drill-ready exploration targets, and
  3. In the Revenue-Nucleus Area, K-Means Cluster Analysis highlighted semi-quantitative alteration styles allowing for robust modelling and vectoring toward zones of high-grade mineralization.

“As an exploration company that embraces the application of new technology, Triumph is pleased by the depth of insight provided by Minerva,” says Jesse Halle, VP Exploration for Triumph Gold. “Having over 145,000 metres of drilling at the Freegold Mountain Project, along with a massive amount of other exploration data, Minerva’s AI engine has helped sharpen the focus of our new Technical Team.”

Brian May, Chief Geoscientist for Triumph Gold adds, “DRIVER has validated Triumph’s stratigraphic and structural interpretations in the Nucleus deposit area. Multielement overlaps will be drill-tested to further confirm our technical team’s interpretations this exploration season.”

Scott Tillman, Minerva Intelligence CEO, is excited about the results. “Our ongoing relationship with Triumph Gold is a win-win for our respective companies,” said Tillman. “Triumph’s embrace of our state-of-the-art mining and exploration software is proof-positive of the value our cognitive AI technology can bring to mining and exploration companies. Triumph’s vast amount of data made the results even better than we had expected.”

Figure 1 – Location of the Freegold Mountain Project and Triumph Gold’s 2021 Minerva Artificial Intelligence study of the Revenue-Nucleus Area.

DRIVER Software 

Minerva Intelligence DRIVER software analyzed and evaluated a comprehensive database of geochemical results compiled from multiple generations of diamond drilling in the Revenue and Nucleus Mineral Resource Deposit areas of the Freegold Mountain Project.

Cost-effective computer reasoning generated orientation data for all elements in the dataset. Further work was performed on key economic elements through automated identification of optimal (“preferred”) orientations, in both planar and linear modes. These results provided potential exploration vectors from Triumph’s database that can be used to identify exploration targets in unexplored regions outside the known resources or mineral prospects.

Additionally, Minerva’s cognitive reasoning platform compared elemental association data from hundreds of past and present mines throughout the world with that of the Revenue-Nucleus Area. Comparisons between Triumph’s resources and known deposit types serve as reliable models upon which geologists can confidently develop their exploration and/or development strategies. 

Nucleus Au-Ag-Cu Deposit

The Nucleus Au-Ag-Cu deposit is a complex deposit involving early porphyry-copper and skarn mineralization overprinted with related epithermal styles of mineralization. Triumph Gold’s technical team has recently modeled the skarn-style mineralization to be preferentially located along favourable horizons within the host Yukon-Tanana metamorphic rock package, as well as at contacts with leucogranite dikes and sills. Past geochronology shows at least some of the Au-Ag-Cu mineralization is coincident with the emplacement of east-trending quartz-feldspar porphyry dikes.

The results of DRIVER’s AI analysis were many, including an independent confirmation of the probability shell developed for the 2020 Resource Estimate which was largely based on dike orientation. The close agreement of the optimal orientation and the rigorously-defined gold shell in the deposit area provides confidence in the Resource Estimate and supports this orientation as an exploration opportunity. Minerva believes this type of agreement may soon be utilized to evaluate other metals as potential co- and by-products on a semi-quantitative basis.

An additional previously unappreciated gold orientation was identified from DRIVER’s outputs at the Nucleus deposit, this time along a northwest-trending structure. This orientation is correlated with a fault corridor and coincident dike swarm and represents an additional opportunity for proximal expansion of, and exploration around, the current resource.

The preferred orientations for copper at the Nucleus deposit area resulted in a largely bimodal distribution, which had not been previously understood. The technical team is currently working on identifying underlying reasons for this distribution, along with other vectors controlling economic mineralization.

Revenue Au-Ag-Cu-Mo-W Deposit

The Revenue Deposit consists of porphyry-copper and related epithermal mineralization within a granodiorite to quartz monzonite intrusive complex. Numerous mineralized zones have been discovered at Revenue, notably the gold-copper-silver-molybdenum-bearing Blue Sky and WAu Porphyry and Epithermal Zones and the proximal mineralized diatreme breccia. Several other mineralized centres have been identified in the Revenue deposit area, including the Guder, Revenue West, Grainger, and Keirsten Zones.

Minerva’s optimal orientation DRIVER results for gold, copper, and molybdenum delineate both the southern and the northeastern contact between the diatreme breccia and the granodiorite as primary locations for further evaluation. The DRIVER results also agree very well with the current lithologic model, providing additional confidence for the technical team’s interpretations.

K-Means Cluster Analysis

K-Means Cluster (KMC) Analysis is an unsupervised learning algorithm meant to identify relationships inherent in a dataset. Unlike supervised learning methods, it does not require labeled training data from which to practice and learn, but rather uncovers native associations within the data itself. For multi-element geochemical data, it identifies potential element assemblages present in the data. If executed carefully and with appropriate data preparation, KMC Analysis can reveal complicated patterns in the data that would otherwise be missed.

Geochemical data was analyzed and evaluated using K-Means Cluster Analysis available in ioGAS software. Clusters (or groups of data records with similar geochemistry) are defined and redefined based on minimizing the distance between the data record and the cluster centre. KMC Analysis concludes when either the change in the distance of each of the data points from the respective centres for assigned cluster approaches a minimum, or the specified number of iterations is reached. Multiple iterations were attempted on the data for both the Nucleus and Revenue Deposit areas using various elements, data transforms and/or initial analytical parameters.

Nucleus Au-Ag-Cu Deposit

K-Means Cluster Analysis and subsequent interpretation though discrimination plots suggest the numerous lithologies within the Nucleus Deposit area have been subjected to variable degrees and styles of potassic alteration. Discrimination plots suggest a small proportion of the data is potassic feldspar (K-spar) alteration, implying an underlying copper-porphyry-style signature. The plots are more suggestive of potassic alteration predominantly expressed as secondary sericite. Based on molar ratios, the most recent alteration event is interpreted to preferentially involve plagioclase (predominantly albite) and is largely independent of K-spar. These observations are consistent with mineralization stemming from the intrusion of quartz-feldspar porphyry dikes from a buried porphyry intrusion.

A large portion of the results in the Nucleus Deposit area are consistent with intrusion-related skarn-type mineralization and closely-associated sulphide mineralization. The geochemistry of these high-iron areas is consistent with the appearance of secondary Ca-rich pyroxene and clinochlore. Triumph geologists believe these results are consistent with the skarn-style mineralization observed in many areas of the deposit.

Revenue Au-Ag-Cu-Mo-W Deposit

K-Means Cluster Analysis and subsequent interpretation though discrimination plots highlight the Blue Sky porphyry and contacts of diatreme breccia as the largest zone of extensive alteration, documenting high values for Ca, K and Na. Barium (Ba) is also anomalous in this zone and extends westward towards Keirsten South Zone. These zones are largely underexplored and represent targets for future work.

Specific locations in the Revenue Deposit are flagged in the K-Means Cluster Analysis work as having been subjected to alkali alteration through Na depletion and potassium addition. Results indicate that the dominant potassic phase is K-rich muscovite with only a small subset interpreted as potassium feldspar alteration. This type of alteration is consistent with the ‘low sulphidation’ deposit model proposed for the deposit area.

Diagnos $ADK $DGNOF Initiates a Clinical Trial Study in the USA for Early Detection and Prevention of Stroke Using it new Application CARA-STROKE

Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today the initiation of a clinical trial study with CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC and conducted at the CommonSpirit Hospital in Chattanooga, to confirm early Proof-of-Concept results that showed a strong potential in the early detection of stroke through the inspection and analysis of the retina.

The clinical trial will be carried out under the direction of Thomas G Devlin M.D., PhD. The IRB study has been approved by an Institutional Review Board (“IRB”) in compliance with all applicable regulations in the USA.

“DIAGNOS will be providing the necessary hardware and technical support during the first phase of the clinical trial. DIAGNOS will have access to all the results tests performed on patients who are admitted to the hospital following a stroke and who meet the study’s inclusion criteria. The tests performed on these patients will include taking images of the retina using DIAGNOS’ CARA-ST technology. The analysis of the retina by our AI application will be done immediately and all medical staff in the clinical trial will have access to it through our FDA-approved Tele-Medicine platform. The initial goal of the first phase of the study is to demonstrate that the results using CARA-ST correlate with the results of the other clinical results. If successful, the second phase would start shortly thereafter and will be screening over 1,000 patients at the same facility and also a new facility in Canada.

DIAGNOS is seeking to demonstrate that CARA-ST will be able to predict the early signs of the condition leading to stroke, based on the micro circulation analysis of the retina image of the patient.

As per CDC-The Center for Disease Control and Prevention, stroke causes 1 out of every 20 deaths, the management of stroke represents a cost of around USD 34 billion per year in the United States. Hence, early diagnosis and treatment to prevent deaths from stroke is a time sensitive necessity.

According to the World Health Organization, 15 million people suffer a stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. High blood pressure contributes to more than 85% of strokes worldwideEurope averages approximately 650,000 stroke related deaths each year.

“According to new reports published by Worldwide Research Institutes, the worldwide market size for Stroke Management will hit over $66 Billion dollars by 2023. DIAGNOS intends to be part of the solution by making available an affordable predictive test to the general public’’ said Mr. André Larente, President of DIAGNOS.

“At DIAGNOS we have continued to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure we stay ahead of our competition worldwide. This year our new stroke management application will be field tested in multiple countries. For our investors this ground-breaking test comes at an ideal time in terms of shareholder value creation as the combination of both CARA-DR and CARA-ST tools will be transformational in helping to monitor the health of existing and future patients with cardiovascular disease,” said Mr. Andre Larente, President of DIAGNOS.

About CommonSpirit

CommonSpirit Health is a non for profit, Catholic health system dedicated to advancing health for all people. It was created in February 2019 through the alignment of Catholic Health initiatives and Dignity Health. With a team of approximately 125,000 physicians and advanced practice clinicians. CommonSpirit Health operates 137 hospitals and more than 1,000 care sites across 21 states. In FY2020, Catholic Health initiatives and Dignity Health had combined revenues of nearly $29.6 billion and provided $4.6 billion in charity care, community benefit and unreimbursed government programs.

Diagnos $ADK $DGNOF Announces Pilot with Sinaloa Hospital

Diagnos (TSXV-ADK) (OTCQB-DGNOF), a leader in early detection of critical health issues, announces today the signing of a 2-month pilot with Hospital Oftalmológico Buena Vista Sinaloa, the largest ophthalmological hospital in Sinaloa State, Mexico.

In Mexico there are 18 million diabetics with a 23% prevalence in people of 20 years or more; the seriousness of these cases is that every hour in the country eight patients die from this disease, since 80% of deaths in Mexico, is related to diabetes. In Sinaloa State, 355,000 thousand cases are reported, of which almost half (175,000) are undiagnosed, with a prevalence of 21% of the population of 20 years or more. Of the 180,000 diagnosed for diabetes, only 30% go to the doctor on a regular basis. According to statistics,

30,000 new cases of diabetes per year are registered in the State of Sinaloa. Diabetic Retinopathy and loss of vision are the 2 biggest problems.

 

“For almost 25 years, we’ve been providing ophthalmic eye care to hundreds of thousands of patients coming from 4 out of 9 States of the Northern Region of Mexico, mainly the west pacific area. Our focus is to provide our specialty services to everybody within one of our 7 eye health programs such as Ophthalmological Consultation, Surgeries, Culture of Prevention of Eye Diseases, Campaign of Free Consultation in Suburban Areas to People in Extreme Poverty, National Museum of Ophthalmology, among others”, mentions Dr. Efraín Romo Santos, Founder and Head of Ophthalmology at Hospital Oftalmológico Buena Vista Sinaloa. “We’re excited to welcome DIAGNOS as we look forward to use a real-life tested technology based on AI, reliable and compliant with the most exigent international standards”, finished Dr. Romo.

“This is a great moment for DIAGNOS as we’ve been proving that our AI and Telemedicine modules helps safety issues around specialists and their staff during this challenging time. We will be demonstrating our service of retina screening to everyone that needs it”, says Mr. Guillermo Moreno, Vice President of DIAGNOS. “Along with Dr. Romo, we’ll provide a turn-key solution to his renowned team of specialists, we’re confident that during the pilot, we’ll deliver a real-time result to the local population by supporting the specialists in their day to day. Finally, we will give hope to patients through the access to eye screening with Dr. Romo’s Institutions”, finished Mr. Moreno.

About Hospital Oftalmológico Buena Vista Sinaloa

At Buena Vista Sinaloa we have been dedicated for more than 24 years to providing efficient ophthalmic treatments for the diagnosis and prevention of eye diseases to each of our clients in Culiacán (HD), Los Mochis and Mazatlan, all three in Sinaloa State, Mexico.

Buena Vista Sinaloa began activities on December 6, 1996, its founder Dr. Efraín Romo Santos, has managed to form an institution with doctors and specialists in ophthalmology, as well as with cutting-edge equipment to care for patients in different states such as Sinaloa, Durango, Baja California Sur and Sonora.

www.diagnos.ca

Diagnos $ADK IRIS, a New Look #Vision Group Company, Teams up with Diagnos in a Multi-Year Agreement to Implement #AI #Technology with Support from INVEST-AI Program

Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce the signing of a multi-year agreement with IRIS The Visual Group (1990) Inc. (“IRIS”), creating a world leading platform launch for the deployment and enhancement of Artificial Intelligence (“AI”) based tests, screening for vascular changes in the retina for optometry clinics.

This milestone agreement with IRIS constitutes a major breakthrough for DIAGNOS’ path to continued global commercialization of its technology solutions.

Initially, implementation of AI at IRIS will cover the province of Quebec in a multi-step approach as per the agreement with the INVEST-AI program. The INVEST-AI Program is managed by IVADO Labs, who receives financial contributions from the Government of Quebec to facilitate the transfer of AI to industry.

“IRIS continues to be at the forefront of implementing technology driven solutions for clinical optometry and optical retail. The combination of technological advancement and clinical experience will help elevate the health care experience and improve patient outcomes. Artificial intelligence will raise our standard when it comes to quality of care and we are eager to collaborate with DIAGNOS,” said Eric Babin, President of IRIS.

In addition, DIAGNOS has entered into a 7-year agreement with New Look Vision Group Inc. (“New Look Vision”), IRIS’ parent company. The New Look Vision network totals 406 locations operating across North America. Outside of the initial implementation, supported by the INVEST-AI Program, this agreement further supports the development and deployment of AI across the broader network.

DIAGNOS algorithms installed in our data center in Montreal will examine the retina images of patients. Patient’s retina images are transmitted using a secure internet connection. DIAGNOS then provides the results of the AI assisted examination back to the optometrist in the form of a report. The optometrist may then use the results of the report to assist in managing treatment and potential referral. DIAGNOS is reimbursed based on a click fee per patient which includes 2 pictures of the retina (left eye and right eye).

“We are extremely pleased to enter into this major agreement with IRIS and New Look Vision, a market leader in North America with more than 400 optical stores. IRIS and New Look Vision are ideal industry partners for the rapid implementation of DIAGNOS’ technologies,” stated André Larente, President of DIAGNOS.

Introduction of AI in medical imaging has changed the market dynamics in recent years and is anticipated to massively influence the growth in the near future. DIAGNOS is committed to develop and market AI-based solutions in the field of medical imaging diagnosis, providing key decision-making support. Though the AI adoption is in the early phase in retinal technologies, rising demand for accuracy, efficiency, and patient safety is anticipated to significantly boost the adoption of DIAGNOS’ AI-enabled medical imaging over the next several years.

“Clinics, optical stores, and diagnostic and research centers are expected to emerge as crucial end users of our image analysis solutions, owing to rising demand for our extremely efficient solutions for better patient outcomes,” said André Larente. “In the future, these segments will account for larger DIAGNOS revenue shares as they increasingly rely on imaging services like CARA (Computer Assisted Retina Analysis), creating significant growth potential for DIAGNOS during its recently launched monetization strategy. Adoption of technologically advanced products such as our proprietary multimodality imaging platforms and benefits associated with the use of our systems, such as high-resolution imaging, convenient use, and flexibility, are contributing to constantly growing demand. Therefore, DIAGNOS is very actively continuing its global roll-out activities and the introduction of even further technologically advanced product updates and the advent of efficient information management systems are expected to drive the market growth in the coming years on a global scale. DIAGNOS has successfully started to transition to its international commercialization strategy, effectively navigating the regulatory landscape, in a highly competitive market, enabling its commercial products to get to market faster than the competition. Launching DIAGNOS’ global sales campaign in the first half of 2021 has allowed the Company to achieve very tangible results for its shareholders already this year, including, but not limited to, the New Look Vision agreement. DIAGNOS is targeting to be cash flow positive by the end of 2021.”

About IRIS and New Look Vision:

IRIS was founded in 1990 in Quebec. Since that time, IRIS has developed into the largest network of optometrists, opticians and ophthalmologists operating under the same banner across Canada. The company’s locations combine clinical optometry and optical retail to provide a unique concept and a commitment to offering top quality products and services in the field of eyecare. For additional information please visit www.iris.ca or consult our LinkedIn page.

New Look Vision is the leading provider of eye care products and services across Canada and entered the United States market in 2020. The Company has retail sales of optical products which can be grouped into four principal categories: (i) prescription and non-prescription eyewear, (ii) contact lenses, (iii) sunglasses, protective eyewear and reading glasses, and (iv) accessories, such as cleaning products for eyeglasses and contact lenses. The Company’s network of stores totals 406 locations. Certain prescription lenses are processed at the Company’s laboratory facility, located in Ville St-Laurent, Québec. For additional information please visit www.newlookvision.ca.

About DIAGNOS:

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

This news release contains forward-looking information. There can be no assurance that forward-lookinginformation will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Mr. André Larente,
PresidentDIAGNOS Inc.
Tel: +1-450-678-8882 ext. 224
Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1 604-507-3377TF: 1-866-503-3377

Diagnos $ADK $DGNOF Enters into Exclusive Distribution Agreement to Access Massive Global Healthcare Market in DACH Countries and Central Europe of Over 140 Million People

Diagnos Inc. TSXV-ADK OTCQB: DGNOF a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of an exclusive distribution agreement with Diagnos Europe GmbH (“Diagnos Europe”), a new partner for DIAGNOS to tackle the strategically important DACH countries in the European market (Germany, Austria, Switzerland) and the surrounding countries Poland, Luxembourg and Liechtenstein in order to prepare a successful market entry for the Company’s products and services in Central Europe, a crucial territory for DIAGNOS with a significant market potential in access of more than 140 million people.

DACH is an abbreviation and D stands for Deutschland (Germany), A, Austria, and CH, Confoederatio Helvetica, (Switzerland). Therefore, it refers to the mostly German-speaking center of Europe. The DACH economy is one of the most stable in the entire world since the end of World War II and it is by far the largest and most promising market for IT and AI in Europe. Diagnos Europe is fully specialized on go-to-market strategies and services in the DACH countries and have developed for DIAGNOS a variety of market entry strategies offering the Company a practical and effective launch pad into the DACH market. 

 Just as the DACH region has become established as Europe’s most important region for the optical market, DIAGNOS will be benefiting from the forthcoming market entry developments and has in addition that long tapping into European potential. The German market, in particular, plays a leading role in the optical industry and thus also for the Company and Diagnos Europe in terms of preparing the implementation of specific sales activities. Alongside the French market, which DIAGNOS is also targeting at the same time, the German-speaking market is the most important in Europe and also the most interesting for the company as a result of its stable growth rates over the past several years. For 2019, the German optical industry was able to record its most successful financial year in a decade, far outperforming other European markets (total sales compared to 2018 were up by 5.4% at EUR 4.7 billion; 2019 thus exceeding all expectations and a continuation of the growth trend that has persisted since 2011. Opticians and optometrists have continuously been able to look forward to a further increase in turnover, which rose to almost EUR 6.5 billion in 2019 and even more in 2020).

Read more:  http://www.diagnos.ca/wp-content/uploads/2021/04/DIAGNOS-Enters-into-Exclusive-Distribution-Agreement-to-Access-Massive-Global-Healthcare-Market-in-DACH-Countries.pdf

@Diagnos $ADK $DGNOF Uses #AI and #Telemedicine to Scan your #Eye for #Health Issues in 16 Countries

In a world where companies toss the term ‘artificial intelligence’ around whenever the office intern figures out how to get a spreadsheet pie chart to update automatically, it’s nice to see a company utilizing actual AI and machine learning in a manner that involves actual intelligence and learning.

Diagnos (ADK.V) is a health tech deal that scans your eye for evidence of health issues, using AI to deliver fast, inexpensive detection that can be used to scan an entire population. 

Click Link for Article:  Diagnos Uses AI and Telemedicine to Scan Your Eye for Health Issues in 16 Countries

http://www.diagnos.ca

 

Diagnos Inc. $ADK and the 3rd Largest #Optical Retailer in Costa Rica Piloting CARA and its #Telemedicine #Technology

Diagnos Inc. $ADK and the 3rd Largest #optical Retailer in Costa Rica Piloting CARA and its #telemedicine #technology

#Healthcare #diabetes #retinaldisease #AI #artificialintelligence #Hypertension #stroke #deeplearning

Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a contract with Óptica Central, the third largest optical chain store in Costa Rica for implementation of CARA across Costa Rica.

“Óptica Central, in collaboration with Aselcom, DIAGNOS’ distributor, are pleased to start screening the population across our optical stores by providing DIAGNOS’ proven AI solution for early detection of eye illnesses, such as Diabetic Retinopathy, as well as preventing blindness caused by diabetes.   There is no doubt that DIAGNOS’ experience in Costa Rica, and in other Latin American countries, has been at the forefront in proving its service with their remarkable technology,” said Mr. Jefrey Salas, CEO of Óptica Central.

“At DIAGNOS we have made our mark in different parts of the world, in collaboration with our partners and different stakeholders, where our AI technology and experience for serving patients has set the standard. We know that Diabetic Retinopathy has become the main cause of blindness worldwide occurring in patients aged 20-64 years. Costa Rica is no different from other countries, with almost 15% of its population over 20 having diabetes, with less than 11% diagnosed. At least 35% have been identified with Diabetic Retinopathy within the diabetic population and 10% are in jeopardy of having severe retinopathy that will affect their vision. Our technology is helping now, through Óptica Central, to fill this gap,” said Mr. Andre Larente, President of DIAGNOS.

About Óptica Central
Founded in July 1983, Óptica Central, located in Alajuela, has become a pioneer in the visual health service offering optics and optometry services. Since its inception, it has been contributing to the visual health of the population with affordable prices and a variety of products such as: Specialties Medical Center, 8 Service Centers / Opticians in the metropolitan area, with more than 40 stores located in national territory of Costa Rica.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224

Diagnos Inc. $ADK AI Image-Based Diagnosis – Commercializing their CARA #Technology

Expanding globally in the AI image based diagnosis sector, Diagnos is actively commercializing their CARA technology.

Diagnos TSXV-ADK is an AI health care company using non-invasive scanning technology done through the eyeball to detect retinal diabetes and hypertension. They are FDA approved, ISO certified and Health Canada approved.

https://investorintel.com/markets/biotech-healthcare/biotech-intel/expanding-globally-in-the-ai-image-based-diagnosis-sector-diagnos-is-actively-commercializing-their-cara-technology/